Truist on Teva Pharma (TEVA): 'We See Upside To Mgmt's Schizo Franchise Guide'
Tweet Send to a Friend
Truist Securities analyst Les Sulewski reiterated a Buy rating and $25.00 price target on Teva ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
